Business
Cytophage Expands Commercialization of Phage Products in Asian Poultry Market
(TheNewswire) Winnipeg – TheNewswire - June 20, 2024 - Cytophage Technologie...
About this update from Cytophage Technologies Ltd.
[{"type":"text","content":"Cytophage Expands Commercialization of Phage Products in Asian Poultry Market\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Winnipeg –\n \n \n TheNewswire\n-\n \n \n June 20, 2024 - Cytophage Technologies Ltd.\n(\n \n \n TSXV:CYTO\n \n \n ) (“\n \n \n Cytophage\n \n \n ” or the “Company”),\n \n \n \n the only publicly traded phage company\nthat is focused on bacteriophage solutions for both animal health and\nhuman health, announces that it has signed of a Letter of Intent (LOI)\nwith a leading Pan-Asian industrial agrifood company headquartered in\nSingapore.\n \n \n \n The LOI outlines a\ncollaboration pathway between Cytophage and this company that operates\nin six countries and derives approximately 80% of its\nmulti-billion-dollar revenue from poultry operations. “Fully\nintegrated poultry producers provide multifaceted opportunities for\nphage products – from eggs to feed to the chickens – creating an\nexciting environment in which to have our phage products improve\nproduction numbers by decreasing bacterial loads”, commented\nCytophage CEO Dr. Steven Theriault. Cytophage anticipates conducting\ntrials with this commercial partner in Q4 of 2024.\n \n \n \n \n Cytophage continues to collaborate with its\ndistribution partner in Bangladesh, recently introducing its\ninnovative lyophilized tablet designed to replace the traditional\nliquid form commonly used in phage therapy.\n \n \n This\nnew form is expected to increase product shelf life and product\nreliability in tropical zones.\n \n \n The Company\nrecognizes the importance of regionalizing phage products to address\nlocal bacterial strains and environmental conditions in order to\nmaximize product adoption and meet customer needs.\n \n \n \n \n \n Cytophage also announces the departure of Chief Commercialization\nOfficer (CCO) Michael Graham to pursue other endeavours.  The\nrecently established Commercialization Committee of the Board,\ntogether with Dr. Theriault and the commercialization team, will work\nto drive initiatives forward and expand Cytophage’s market presence.\n“We will continue to explore and secure new commercialization\nopportunities in various marketplaces” stated Dr. Theriault.\n ȁ...